Shire PLC (LON:SHP)‘s stock had its “outperform” rating reaffirmed by equities researchers at Credit Suisse Group AG in a report issued on Friday. They presently have a GBX 5,200 ($67.88) price target on the biopharmaceutical company’s stock. Credit Suisse Group AG’s price objective would suggest a potential upside of 1.68% from the stock’s previous close.

A number of other analysts have also recently issued reports on SHP. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a report on Wednesday, June 15th. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 6,300 ($82.23) price target (up from GBX 5,600 ($73.10)) on shares of Shire PLC in a research report on Monday, August 1st. Jefferies Group boosted their price target on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the stock a “buy” rating in a research report on Wednesday, August 3rd. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, June 14th. Finally, Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($78.32) price target on shares of Shire PLC in a research report on Monday, September 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of GBX 5,828 ($76.07).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 5114.00 on Friday. The stock’s market capitalization is GBX 34.92 billion. The firm has a 50-day moving average of GBX 4,981.22 and a 200 day moving average of GBX 4,556.22. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00.

The company also recently declared a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.

In other news, insider Dominic Blakemore purchased 133 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average cost of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.